Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related

Read the full 260 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE